Story excerpt provided by Crain’s Cleveland Business.
As Athersys Inc. moves toward a Phase 3 clinical trial for its stroke treatment, the Cleveland-based biotech company has received a federal designation that CEO Gil Van Bokkelen says is a recognition of the therapy’s importance. The U.S. Food & Drug Administration awarded Athersys’ clinical program for stroke “Fast Track Designation,” an expedited drug development and review program for new drugs or biologics to treat serious or life-threatening conditions. Written by Lydia Coutré.
Click here to read the complete article.
Originally published May 28, 2017.